CDI of the combination of sorafenib and celecoxib in HepG2 and Huh7 cells.

Figshare2015-12-02 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/_CDI_of_the_combination_of_sorafenib_and_celecoxib_in_HepG2_and_Huh7_cells_/717306 数据链接链接失效反馈

官方服务：

资源简介：

CDI of the combination of sorafenib and celecoxib in HepG2 and Huh7 cells.

创建时间：

2015-12-02

In Vitro Activities of Gemifloxacin versus Five Quinolones and Two Macrolides against 271 Spanish Isolates of Legionella pneumophila: Influence of Charcoal on Susceptibility Test Results

抗菌药物敏感性

体内药效评估

The MICs at which 90% of isolates are inhibited for gemifloxacin, trovafloxacin, and grepafloxacin were low (≤0.01 μg/ml) for 271 Legionella isolates when they were determined by the broth microdiluti

PubMed Central40

DataSheet_1_Modulation of ERCC1-XPF Heterodimerization Inhibition via Structural Modification of Small Molecule Inhibitor Side-Chains.pdf

DNA修复抑制剂

癌症药物协同效应

Inhibition of DNA repair enzymes is an attractive target for increasing the efficacy of DNA damaging chemotherapies. The ERCC1-XPF heterodimer is a key endonuclease in numerous single and double stran

NIAID Data Ecosystem30

The data used in this article, including raw chemical data and results from in vitro/in vivo experiments

肌肉萎缩药物实验

体内药效评估

The folder contains the raw data from cell and animal experiments, and the data analysis conducted using R for visualization and statistical purposes. In vitro - Statistical analysis and visualization

NIAID Data Ecosystem30

Mitoxantrone-liposome sensitizes Flt3-ITD acute myeloid leukemia to gilteritinib treatment

FLT3靶向治疗

癌症药物协同效应

FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in acute myeloid leukemia (AML), and is associated with a poor prognosis and high relapse rate. Gilteritinib, as a second-generati

NIAID Data Ecosystem30

Inhibition of the mRNA-binding protein IGF2BP1 suppresses proliferation and sensitizes neuroblastoma cells to chemotherapeutics

母细胞瘤靶向治疗

癌症药物协同效应

Gain at chromosome 17q21 in neuroblastoma and is associated with a poor prognosis, independent of MYCN amplification status. Several potential proto-oncogenes have been identified in this region, one

NIAID Data Ecosystem30

CDI of the combination of sorafenib and celecoxib in HepG2 and Huh7 cells.

资源简介：

相关数据集